The spotlight on H. Lundbeck AS's Phase III drug idalopirdine doesn't shine quite as bright as the lights illuminating other late-stage Alzheimer's disease (AD) programs, since it treats the symptoms and not the underlying cause of AD. But the Danish company believes that even when disease-modifying treatments are available, there still will be a considerable need for symptomatic therapies.
Executive Vice President of Research and Development Anders Gersel Pedersen told Scrip that a combination of approaches are needed, so Lundbeck is working on drugs to treat Alzheimer's symptoms and other therapies that may slow the disease's progression
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?